OCT 08, 2020 10:00 AM PDT

The importance of liquid biopsy MSI for studying tumors and immunotherapy applications

Speaker
  • Chief Medical Officer - Circulogene
    Biography

      Dr. Paul Walker is a graduate of the Indiana University School of Medicine and Associate Professor Emeritus at the Brody School of Medicine at East Carolina University in Greenville, NC, where he served as Director of Thoracic Oncology and Director of the Hematology/Oncology Fellowship Program. He currently is Chief Medical Officer of Circulogene. Published cancer research has focused on immune therapy dating back to IL-2, immune checkpoint blockade in combination with ablative radiation therapy, managing immune toxicities and racial disparities in lung cancer treatment. Current research focus is the clinical utility of liquid biopsies in early stage lung cancers and integrating non-driver co-mutations into cancer treatment decision making.


    Abstract

    DATE: October 8, 2020

    TIME:  10:00am PDT, 1:00pm EDT

     

    Microsatellite instability (MSI) has evolved as a marker of potential hereditary cancer risk and is now a tissue agnostic immune biomarker with a broad reaching impact across cancer screening, tumor biology and cancer treatment outcomes. MSI-high is the first tissue agnostic predictive immune biomarker achieving FDA approval for immune checkpoint blockade therapy extended across multiple cancers irrespective of the anatomical tissue of origin and solely based upon a confirmed MSI-high status tumor biology. MSI is favorably predictive of anti-angiogenesis and radiation therapy benefit yet is an adversely detrimental predictive marker for cytotoxic chemotherapy. Intra- and inter-tumoral heterogeneity and dynamic cancer clonal evolution can be a limitation of tissue biopsies. Liquid biopsy MSI can overcome these dynamic clonal heterogeneity issues and will be able to extend MSI testing and potential durable immunotherapy survival benefits in the future to patients that otherwise have tissue acquisition limitations.

    MSI guided cancer treatment is now extending to earlier stages of cancers based upon tumor biology and not anatomic stage. MSI may be sporadic or can result from germline MMR mutations defining the Lynch Syndrome. This hereditary identification has tremendous impact for both the individual with their cancer treatment decisions but can also guide more effective focused cancer screening of affected family members. MSI-high is a distinct tumor biology state with a differing cancer treatment benefit. Integrating liquid MSI as a potential dynamic response biomarker in cancer treatment clinical trials as well as tumor biology translational research studies with tumor mutational burden, co-mutations, angiogenesis, and other components of an immune hot versus cold tumor microenvironment are needed and is an important step forward to further extend the potential curability of cancer treatment.

     

    Learning Objectives:

    • Learn how MSI status can be detected in liquid biopsy samples. Review the cancer treatment outcomes in MSI tissue agnostic cancers.
    • Outline the MSI tumor biology interaction with other immune biomarkers, oncogenic pathways, and mutations in cancer treatment.
    • Discuss the future potential cancer research and clinical utility of liquid biopsy MSI.

     

     

    Webinars will be available for unlimited on-demand viewing after live event.

     

    LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.


    Show Resources
    You May Also Like
    MAY 11, 2021 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    MAY 11, 2021 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
    DEC 02, 2020 8:00 AM PST
    C.E. CREDITS
    DEC 02, 2020 8:00 AM PST
    DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
    OCT 29, 2020 6:00 AM PDT
    C.E. CREDITS
    OCT 29, 2020 6:00 AM PDT
    Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
    APR 01, 2021 8:00 AM PDT
    C.E. CREDITS
    APR 01, 2021 8:00 AM PDT
    Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    Loading Comments...
    Show Resources
    Attendees
    • See more